SCF+G-CSF treatment in the chronic phase of experimental stroke leads to stable and long-term improvements in somatosensory motor function as compared to SCF and G-CSF alone treatments [27], and enhances neural network regrowth and synaptogenesis [28, 29]. This evidence concerns the gene CSF3 and stroke disorder.